Femoral Nerve Block for Analgesia After Anterior Cruciate Ligament Reconstruction

Femoral Nerve Block Using 0.25% Versus 0.5% Bupivacaine for Analgesia After Arthroscopic Anterior Cruciate Ligament Reconstruction

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01593566

Acronym

FNB for ACLR

Enrollment

100

Registered

2012-05-08

Start date

2011-04-30

Completion date

2013-06-30

Last updated

2015-04-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Analgesia After ACL Reconstruction

Keywords

femoral nerve block

Brief summary

Femoral nerve block using 0.25% bupivacaine or 0.5% bupivacaine provides a longer time for analgesia after Anterior Cruciate Ligament (ACL) reconstruction.

Interventions

DRUG0.25% Bupivacaine

Femoral nerve block using 0.25% versus 0.5% bupivacaine

DRUG0.5% Bupivacaine

Femoral nerve block using 0.25% versus 0.5% bupivacaine for analgesia after ACL reconstruction

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients scheduled for ACL reconstruction * ASA physical status I-II * Body weight \> or = 50 kg.

Exclusion criteria

* Patients with redo ACL reconstruction * Contraindication to neuraxial block * allergy to local anesthetics, sulfa, NSAIDs, morphine, paracetamol * Patients with communication problem

Design outcomes

Primary

Measure	Time frame
time to first analgesic requirement	48 hr

Secondary

Measure	Time frame
pain score scale	48 hr

Countries

Thailand

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026